AUTL: Autolus Therapeutics Plc
About
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Current Value
$2.971 Year Return
Current Value
$2.971 Year Return
Key Details
Market Cap
$785.05M
P/E Ratio
-2.44
1Y Stock Return
-27.16%
1Y Revenue Growth
82.71%
Dividend Yield
0.00%
Price to Book
1.6
Strategies that include AUTL
Stock's related to AUTL
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACLX | 44.01% | $4.74B | +69.19% | 0.00% |
| KRNT | 35.75% | $1.48B | +73.34% | 0.00% |
| RCKY | 34.14% | $155.86M | -17.74% | 2.95% |
| PLRX | 32.81% | $778.32M | -9.55% | 0.00% |
| RC | 31.87% | $1.22B | -27.41% | 15.95% |
| LOPE | 31.52% | $4.70B | +18.15% | 0.00% |
| BMBL | 31.39% | $845.98M | -43.90% | 0.00% |
| ZYME | 31.37% | $1.03B | +79.68% | 0.00% |
| CARS | 31.28% | $1.20B | -2.01% | 0.00% |
| KALV | 31.08% | $440.88M | +17.08% | 0.00% |
| MG | 30.96% | $282.81M | +42.06% | 0.00% |
| CNOB | 30.66% | $1.03B | +41.32% | 2.65% |
| ARI | 30.63% | $1.27B | -14.15% | 14.16% |
| SRI | 30.02% | $166.13M | -63.46% | 0.00% |
| CWH | 29.63% | $1.36B | +5.90% | 2.22% |
| DLX | 29.59% | $1.01B | +24.44% | 5.30% |
| EGHT | 29.38% | $351.48M | -7.88% | 0.00% |
| CLFD | 29.20% | $398.66M | +4.48% | 0.00% |
| XWDIX | 29.06% | - | - | 11.82% |
| GPMT | 28.88% | $173.85M | -33.97% | 13.01% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PTMN | 0.02% | - | - | 16.06% |
| CPB | -0.03% | $12.96B | +7.08% | 3.40% |
| PAYX | 0.04% | $50.62B | +18.84% | 2.73% |
| HSY | 0.05% | $34.45B | -10.68% | 3.21% |
| KO | 0.09% | $269.63B | +7.86% | 3.07% |
| AXS | -0.16% | $7.14B | +55.12% | 2.06% |
| BTSG | -0.16% | $3.25B | +43.46% | 0.00% |
| SFL | -0.18% | $1.55B | -4.05% | 9.77% |
| ACRS | -0.18% | $327.87M | +415.67% | 0.00% |
| HPE | 0.20% | $27.96B | +37.84% | 2.42% |
| AES | -0.23% | $9.78B | -17.86% | 5.04% |
| CPNG | 0.23% | $43.51B | +49.69% | 0.00% |
| TCTM | 0.23% | $8.10M | -42.99% | 0.00% |
| LAUR | 0.24% | $2.83B | +41.77% | 0.00% |
| FL | -0.26% | $2.16B | -0.61% | 0.00% |
| EME | -0.28% | $23.65B | +140.34% | 0.18% |
| LICY | -0.28% | $53.41M | -60.56% | 0.00% |
| PG | -0.28% | $402.15B | +14.14% | 2.33% |
| PSQH | -0.29% | $79.26M | -57.46% | 0.00% |
| FTNT | -0.34% | $69.59B | +72.67% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -13.63% | $16.69M | -11.56% | 0.00% |
| UUU | -12.61% | $4.97M | -41.89% | 0.00% |
| CHD | -12.22% | $27.18B | +19.50% | 1.03% |
| RCL | -12.06% | $63.10B | +123.86% | 0.17% |
| WM | -11.86% | $87.92B | +27.58% | 1.34% |
| NVO | -11.33% | $342.62B | -0.15% | 1.40% |
| RELY | -10.59% | $3.96B | -7.42% | 0.00% |
| NARI | -10.20% | $2.98B | -11.66% | 0.00% |
| FCN | -9.64% | $7.10B | -10.74% | 0.00% |
| PAYC | -9.25% | $12.12B | +21.78% | 0.69% |
| STG | -8.46% | $35.67M | +7.92% | 0.00% |
| YOU | -8.28% | $2.50B | +34.63% | 1.10% |
| IP | -8.06% | $20.09B | +78.02% | 3.20% |
| OHI | -7.96% | $10.84B | +26.02% | 6.71% |
| SHEL | -7.83% | $205.19B | -1.07% | 4.20% |
| AMED | -7.78% | $2.95B | -3.95% | 0.00% |
| CL | -7.76% | $76.48B | +22.25% | 2.12% |
| NCLH | -7.65% | $11.58B | +83.81% | 0.00% |
| PGR | -7.62% | $149.10B | +57.29% | 0.45% |
| GEV | -7.56% | $93.72B | +159.05% | 0.00% |
ETF's related to AUTL
News
SeekingAlpha
Autolus Therapeutics' AUCATZYL shows strong potential despite safety concerns. Find out why AUTL stock is a Buy.
Finnhub
On November 8, 2024 Autolus, Inc. announced that the FDA has approved AUCATZYL for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ....
Yahoo
Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset Aucatzyl represents a de-risking event for the company’s technology platform and manufacturing facilities and the label granted by the FDA supports Aucatzyl’s differentiated safety profile, contends the firm, which sees “a significant dislocation between the company’s fundamental valuation and current market value.” Published first on TheFly – the ult
Yahoo
Autolus Therapeutics ( NASDAQ:AUTL ) Third Quarter 2024 Results Key Financial Results Net loss: US$82.1m (loss widened...
Yahoo
Despite a decline in NAV and portfolio value, Syncona Ltd (LSE:SYNC) remains optimistic with strategic investments and leadership enhancements.
Yahoo
Autolus Therapeutics PLC (AUTL) reports significant progress with FDA approval of AUCATZYL, robust financial positioning, and strategic challenges in its Q3 2024 earnings call.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.